References
- Siddall PJ, Loeser JD. Pain following spinal cord injury. Spinal Cord 2001;39:63–73.
- Siddall PJ, McClelland JM, Rutkowski SB, Cousins MJ. A longitudinal study of the prevalence and characteristics of pain in the first 5 years following spinal cord injury. Pain 2003;103:249–257.
- Burke D, Fullen BM, Stokes D, Lennon O. Neuropathic pain prevalence following spinal cord injury: a systematic review and meta-analysis. Eur J Pain 2017;21:29–44.
- Dijkers M, Bryce T, Zanca J. Prevalence of chronic pain after traumatic spinal cord injury: a systematic review. J Rehabil Res Dev 2009;46:13.
- Werhagen L, Budh CN, Hultling C, Molander C. Neuropathic pain after traumatic spinal cord injury – relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord 2004;42:665–673.
- Closs SJ, Staples V, Reid I, Bennett MI, Briggs M. Managing the symptoms of neuropathic pain: an exploration of patients’ experiences. J Pain Symptom Manage 2007;34:422–433.
- Saunders LL, Krause JS, Focht KL. A longitudinal study of depression in survivors of spinal cord injury. Spinal Cord 2012;50:72–77.
- Hoffman JM, Bombardier CH, Graves DE. A longitudinal study of depression from 1 to 5 years after spinal cord injury. YAPMR 2011;92:411–418.
- Gruener H, Zeilig G, Laufer Y, Blumen N, Defrin R. Increased psychological distress among individuals with spinal cord injury is associated with central neuropathic pain rather than the injury characteristics. Spinal Cord 2018;56:176–184.
- Calmels P, Mick G, Perrouin-Verbe B, Ventura M. Neuropathic pain in spinal cord injury: identification, classification, evaluation. Ann Phys Rehabil Med 2009;52:83–102.
- Putzke JD, et al. Pain classification following spinal cord injury: the utility of verbal descriptors. Spinal Cord 2002;40:118–127.
- Hicken BL, Putzke JD. R. J. Classification of pain following spinal cord injury: literature review and future directions. In: Burchiel KJ, RP Yersierski, (ed.) Spinal Cord Injury Pain: Assessment, Mechanisms, Management. Seattle: International Association for the Study of Pain; 2002. p. 25–38.
- Bryce TN, et al. International spinal cord injury pain classification: part I. background and description. Spinal Cord 2012;50:413–417.
- Cardenas DD, Emir B, Parsons B. Examining the time to therapeutic effect of pregabalin in spinal cord injury patients with neuropathic pain. Clin Ther 2015;37:1081–1090.
- Bryce TN, Dijkers MPJM, Ragnarsson KT, Stein AB, Chen B. Reliability of the Bryce/Ragnarsson spinal cord injury pain taxonomy. J Spinal Cord Med 2006;29:118–132.
- Cardenas DD, Jensen MP. Treatments for chronic pain in persons with spinal cord injury: a survey study. J Spinal Cord Med 2006;29:109–117.
- Carbone LD, et al. Morbidity following lower extremity fractures in men with spinal cord injury. Osteoporos Int 2013;24:2261–2267.
- Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA - J Am Med Assoc 2016;315:1624–1645.
- Krause JS, Clark JMR, Saunders LL. Pain medication misuse among participants with spinal cord injury. Spinal Cord 2015;53:630–635.
- Hans G, Robert D, Verhulst J, Vercauteren M. Lidocaine 5% patch for localized neuropathic pain : progress for the patient, a new approach for the physician. Clin Pharmacol Adv Appl 2010;2:65–70.
- Lidoderm Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020612s012lbl.pdf.
- Lidocaine Jelly Package Insert. Available from https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=50452ed9-e5f2-4546-9eca-9518f9b654a9&type=display.
- Trbovich M, Yang H. Capsaicin 8% patch for central and peripheral neuropathic pain of persons with incomplete spinal cord injury. Am J Phys Med Rehabil / Assoc Acad Physiatr 2015;94:e66–e72.
- Min K, Oh Y, Lee S-H, Ryu JS. Symptom-based treatment of neuropathic pain in spinal cord-injured patients. Am J Phys Med Rehabil 2015;1; doi:https://doi.org/10.1097/PHM.0000000000000382.
- Siddall PJ, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67:1792–1800.
- Mehta S, McIntyre A, Dijkers M, Loh E, Teasell RW. Gabapentinoids are effective in decreasing neuropathic pain and other secondary outcomes after spinal cord injury: a meta-analysis. Arch Phys Med Rehabil; 2014;95:2180–2186.
- Lyrica Package Insert. Available from http://labeling.pfizer.com/ShowLabeling.aspx?id=561.
- Cardenas DD, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 2013;80:533–539.
- Carbone LD, et al. Antiepileptic drug use, falls, fractures and BMD in postmenopausal women: findings from the Women’s Health Initiative (WHI). J Bone Miner Res 2009. 091019190442039–25. doi:https://doi.org/10.1359/jbmr.091027.
- Shiek Ahmad B, et al. Falls and fractures in patients chronically treated with antiepileptic drugs. Neurology 2012;79:145–151.
- Maximos M, Chang F, Patel T. Risk of falls associated with antiepileptic drug use in ambulatory elderly populations. Can Pharm J / Rev des Pharm du Canada 2017;150:101–111.
- Schladen M, Groah S. State of the science on cardiometabolic risk after spinal cord injury: recap of the 2013 ASIA pre-conference on cardiometabolic disease. Top Spinal Cord Inj Rehabil 2014;20:105–112.
- Bombardier CH, Adams LM, Fann JR, Hoffman JM. Depression trajectories during the first year after spinal cord injury. Arch Phys Med Rehabil 2016;97:196–203.
- Craig A, Tran Y, Middleton J. Psychological morbidity and spinal cord injury: a systematic review. Spinal Cord 2009;47:108–114.
- Cao Y, Massaro JF, Krause JS, Chen Y, Devivo MJ. Suicide mortality after spinal cord injury in the United States: injury cohorts analysis. Arch Phys Med Rehabil 2014;95:230–235.
- Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia 2011;52:826–836.
- DeVivo MJ, Black KJ, Richards JS, Stover SL. Suicide following spinal cord injury. Paraplegia 1991;29:620–627.
- Watson JC, Sandroni P. Central neuropathic pain syndromes. Mayo Clin Proc 2016;91:372–385.
- Neurontin Package Insert. Available from http://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=630.
- Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV, Loubser PG. Comparison of effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007;88:1547–1560.
- Hagen EM, Rekand T. Management of neuropathic pain associated with spinal cord injury. Pain Ther 2015;4:51–65.
- To T-P, et al. Gabapentin for neuropathic pain following spinal cord injury. Spinal Cord 2002;40:282–285.
- Levendoglu F, et al. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine (Phila Pa 1976) 2004;29:743–751.
- Dworkin RH, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237–251.
- Pérez C, Navarro A, Saldaña MT, Masramón X, Rejas J. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther 2010;32:1357–1370.
- Tai Q, et al. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med 2002;25:100–105.
- Haller H, Leblhuber F, Trenkler J, Schmidhammer R. Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin. 2003: 977–981. doi:https://doi.org/10.1007/s00702-003-0022-x.
- Saulino M. Spinal cord injury pain. Phys Med Rehabil Clin N Am 2014;25:397–410.
- Attal N, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113–1e88.
- Guy SD, et al. The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord: recommendations for treatment. Spinal Cord 2016;54:S14–S23.
- Tzellos TG, Papazisis G, Amaniti E, Kouvelas D. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. Eur J Clin Pharmacol 2008;64:851–858.
- Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs 2017;77:403–426.
- Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction 2016;111:1160–1174.
- Gilron I, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324–1334.
- Gomes T, et al. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case–control study. PLOS Med 2017;14:1–13. e1002396.
- Keppra Package Insert. Avaiable from https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021035s078s080,021505s021s024lbl.pdf.
- Finnerup NB, et al. Levetiracetam in spinal cord injury pain: a randomized controlled trial. Spinal Cord 2009;47:861–867.
- Guy S, Mehta S, Leff L, Teasell R, Loh E. Anticonvulsant medication use for the management of pain following spinal cord injury: systematic review and effectiveness analysis. Spinal Cord 2014;52:89–96.
- Wiffen PJ, Derry S, Moore RA, Lunn MPT. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev 2014;(1):CD010943. doi:https://doi.org/10.1002/14651858.CD010943.
- Galluzzi K. Managing neuropathic pain. J Am Osteopat Assoc 2007;107:ES39–ES48.
- Wolfe GI, Trivedi JR. Painful peripheral neuropathy and its nonsurgical treatment. Muscle and Nerve 2004;30:3–19.
- Trileptal Package Insert. Available from https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/trileptal.pdf.
- Agarwal N, Joshi M. Effectiveness of amitriptyline and lamotrigine in traumatic spinal cord injury-induced neuropathic pain: a randomized longitudinal comparative study. Spinal Cord 2017;55:126–130.
- Finnerup NB, Sindrup SH, Bach FW, Johannesen IL JT. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 2002;96:375–383.
- Lamotrigine Package Insert. Available from https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF.
- Lamictal Package Insert. Available from https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lamictal/pdf/LAMICTAL-PI-MG.PDF.
- Drewes AM, Andreasen A, Poulsen LH. Valproate for treatment of chronic central pain after spinal cord injury. A double-blind cross-over study. Paraplegia 1994;32:565–569.
- Dinoff B, Richards S, Ness TJ. Clinical notes use of topiramate for spinal cord injury-related pain. J Spinal Cord Med 2003;26:401–403.
- Topiramate Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020844s041lbl.pdf.
- Topamax package insert. Available from https://www.topamax.com/files/topamax.pdf.
- Epocrates. Available from https://online.epocrates.com/drugs/131604/topiramate/Drug-Interactions.
- Finnerup NB, Baastrup C. Spinal cord injury pain: mechanisms and management. Curr Pain Headache Rep 2012;16:207–216.
- Mehta S, McIntyre A, Janzen S, Loh E, Teasell R. Systematic review of pharmacologic treatments of pain after spinal cord injury: an update. Arch Phys Med Rehabil 2016;97:1381–1391 .e1.
- Cardenas DD, et al. Efficacy of amitriptyline for relief of pain in spinal cord injury: results of a randomized controlled trial. Pain 2002;96:365–373.
- Mehta S, Guy S, Lam T, Teasell R, Loh E. Antidepressants are effective in decreasing neuropathic pain after SCI: a meta-analysis. Top Spinal Cord Inj Rehabil 2015;21:166–173.
- Teasell RW, et al. A systematic review of pharmacologic treatments of pain after spinal cord injury. Arch Phys Med Rehabil 2010;91:816–831.
- American Geriatrics Society 2015 Updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–2246.
- Attal N, Mazaltarine G, Perrouin-Verbe B, Albert T. Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous). Ann Phys Rehabil Med 2009;52:124–141.
- Ray W. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004;75:234–241.
- Vranken JH, et al. Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 2011;152:267–273.
- Richards JS, et al. Efficacy of venlafaxine XR for the treatment of pain in patients with spinal cord injury and major depression: a randomized, controlled trial. Arch Phys Med Rehabil 2015;96:680–689.
- Cymbalta Package Insert. Available from http://pi.lilly.com/us/cymbalta-pi.pdf.
- Effexor XR Package Insert. Available from http://labeling.pfizer.com/showlabeling.aspx?ID=100.
- Karlsson A-K. Autonomic dysfunction in spinal cord injury: clinical presentation of symptoms and signs. Prog Brain Res 2006;152:1–8.
- Dworkin R, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3–S14.
- Davidoff G, Guarracini M, Roth E, Sliwa J, Yarkony G. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study. Pain 1987;29:151–161.
- Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57:1583–1588.
- Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain 2000;16:6–11.
- Shah TH, Moradimehr A. Review article: bupropion for the treatment of neuropathic pain. Am J Hosp Palliat Med 2010;27:333–336.
- Yang ML, et al. Efficacy and safety of lithium carbonate treatment of chronic spinal cord injuries: a double-blind, randomized, placebo-controlled clinical trial. Spinal Cord 2012;50:141–146.
- Weinsanto I, et al. Lithium reverses mechanical allodynia through a mu opioid-dependent mechanism. Mol Pain; 2018;14:1–18. doi:https://doi.org/10.1177/1744806917754142.
- Lithium Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017812s028,018421s027lbl.pdf.
- Moore RA, Chi C-C, Wiffen PJ, Derry S, Rice ASC. Oral nonsteroidal anti-inflammatory drugs for neuropathic pain. In: Moore RA, (ed.) Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2015. doi:https://doi.org/10.1002/14651858.CD010902.pub2.
- Pountos I, Georgouli T, Calori GM, Giannoudis PV. Do nonsteroidal anti-inflammatory drugs affect bone healing? A critical analysis. Sci World J 2012;2012:1–14.
- Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci 2013;16:821–847.
- Wiffen PJ, et al. Paracetamol (Acetaminophen) with or without codeine or dihydrocodeine for neuropathic pain in adults. In: Moore RA, (ed.) Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd; 2016. doi:https://doi.org/10.1002/14651858.CD012227.pub2.
- Shinozaki T, Yamada T, Nonaka T, Yamamoto T. Acetaminophen and non-steroidal anti-inflammatory drugs interact with morphine and tramadol analgesia for the treatment of neuropathic pain in rats. J Anesth 2015;29:386–395.
- Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury. Clin J Pain 2009;25:177–184.
- Tramadol Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022370s000lbl.pdf.
- Tramadol ER Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021692s015lbl.pdf.
- Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21–29.
- Hagenbach U, et al. The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2007;45:551–562.
- Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2018. doi:https://doi.org/10.1002/14651858.CD012182.pub2.
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag 2008;4:245–259.
- Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol. Neuropsychopharmacology 2018;43:142–154.
- Dronabinol Package Insert. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf.
- Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM. Effect of dronabinol on central neuropathic pain after spinal cord injury. Am J Phys Med Rehabil 2010;89:840–848.
- SATIVEX® Pipeline. Available from https://www.gwpharm.com/healthcare-professionals/product-pipeline#.
- Chiou-Tan FY, et al. Effect of mexiletine on spinal cord injury dysesthetic pain. Am J Phys Med Rehabil; 1996;75:84–87.
- Injectable Salmon Calcitonin. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017808s034lbl.pdf.
- Salmon Calcitonin Nasal Spray. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020313s036lbl.pdf.
- Humble SR. Calcitonin for acute neuropathic pain associated with spinal cord injury. Anaesth Intens Care 2011;39:682–686.